Symbol
| EPHB4
| contributors: mct - updated : 27-01-2016
|
HGNC name
| EPH receptor B4
|
HGNC id
| 3395
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
constitutional
|  
|  
| --other
|  
|
expressed in ovarian cancers and significantly associated with advanced stage of disease and the presence of ascite | tumoral
|  
|  
| --over
|  
|
in a variety of different epithelial cancers including prostate where it has been shown to be involved in survival, migration and angiogenesis | tumoral
|  
|  
| --over
|  
|
in transitional cell carcinoma of the bladder | tumoral
|  
|  
| --over
|  
|
in papillary thyroid carcinoma cell lines | |
Variant & Polymorphism
|
| |
Candidate gene
Marker
Therapy target
|
System | Type | Disorder | Pubmed |
cancer | urinary | | |
therapeutic compounds targeting EPHB4 have potential for diagnosing and treating transitional cell carcinoma of the bladder | cancer | reproductive | ovary | |
inhibition of EPHB4 may hence have prognostic and therapeutic utility in ovarian carcinoma | cancer | endocrine | thyroid | |
might be a potential therapeutic target in papillary thyroid carcinoma |
| | | |
| deletions of the gene reveal its essential roles for conduit vessel development in mice, suggesting similar functions during human vascular development and deregulation in vascular malformations |